Note:The soft agar clonogenic assay was used to produce survival curves for several human bladder transitional cell carcinomas when exposed to mitomycin C, adriamycin, thiotepa, DMSO, retinoic acid and sulphapentosan sodium. These curves indicated in vitro growth inhibition with mitomycin C, adriamycin, and thiotepa, but not with DMSO, retinoic acid and sulphapentosan sodium. A resistantsubpopulation of cells was documented with some tumors after exposure to mitomycin C and adriamycin. Growth of human bladder tumor stem cells in soft agar was not associated statistically with the grade of the tumor. The soft agar clonogenic assay was found to have potential as a research tool for the study of tumor responses to standard chemotherapeutic age...
We examined the chemosensitivity of adenocarcinoma of the cervix in advanced, recurrent and high ris...
The successful development of a soft agar clonogenic assay for human tumor stem cells provides an in...
Assessment of ex-vivoefficacy of immunotherapeutic agents in intermediate-risk and high-risknon-musc...
The cytotoxic response of cancer cells to chemotherapeutic drugs may be influenced by the developmen...
The concept that continuous cell lines derived from one histological type of tumour provide an in vi...
Different methods were compared for the in vitro evaluation of the therapeutic effects of the antine...
The administration of antibody conjugates for cancer therapy is now proving to be of clinical value....
Introduction: The glycoprotein P-170, causing drug efflux from the cells, may represent at least one...
An in vitro chemosensitivity test on permanent cell lines from adeno-, epidermoid and small cell car...
An anti-carcinoembryonic antigen (CEA) monoclonal antibody (mAb 6D1.1) was evaluated in vitro and in...
The recent development of hybridoma technology, providing monoclonal antibodies (MoAb) of predefined...
© 2011 Dr. Carmel Jo PezaroBackground: Non-muscle invasive bladder cancer is a common condition. Aft...
Bladder cancer can be viewed as a prototype for carcinogen-induced neoplasia. This has been demonstr...
A)-C) Colony survival assays of bladder cancer cell lines RT112 and T24. Cells were treated without ...
Purpose: a factor pertinent to the design of cancer chemotherapy is multidrug resistance. Research i...
We examined the chemosensitivity of adenocarcinoma of the cervix in advanced, recurrent and high ris...
The successful development of a soft agar clonogenic assay for human tumor stem cells provides an in...
Assessment of ex-vivoefficacy of immunotherapeutic agents in intermediate-risk and high-risknon-musc...
The cytotoxic response of cancer cells to chemotherapeutic drugs may be influenced by the developmen...
The concept that continuous cell lines derived from one histological type of tumour provide an in vi...
Different methods were compared for the in vitro evaluation of the therapeutic effects of the antine...
The administration of antibody conjugates for cancer therapy is now proving to be of clinical value....
Introduction: The glycoprotein P-170, causing drug efflux from the cells, may represent at least one...
An in vitro chemosensitivity test on permanent cell lines from adeno-, epidermoid and small cell car...
An anti-carcinoembryonic antigen (CEA) monoclonal antibody (mAb 6D1.1) was evaluated in vitro and in...
The recent development of hybridoma technology, providing monoclonal antibodies (MoAb) of predefined...
© 2011 Dr. Carmel Jo PezaroBackground: Non-muscle invasive bladder cancer is a common condition. Aft...
Bladder cancer can be viewed as a prototype for carcinogen-induced neoplasia. This has been demonstr...
A)-C) Colony survival assays of bladder cancer cell lines RT112 and T24. Cells were treated without ...
Purpose: a factor pertinent to the design of cancer chemotherapy is multidrug resistance. Research i...
We examined the chemosensitivity of adenocarcinoma of the cervix in advanced, recurrent and high ris...
The successful development of a soft agar clonogenic assay for human tumor stem cells provides an in...
Assessment of ex-vivoefficacy of immunotherapeutic agents in intermediate-risk and high-risknon-musc...